Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70420 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Iek Leng Cheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infection, Immunity and Inflammation Research & Teaching Department, UCL GOS Institute of Child Health, University of London, London, UK. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Models, Biological, Immunologic Deficiency Syndromes, Primary Immunodeficiency Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Education England (HEE)/NIHR.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aims
Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to secondary antibody deficiencies and a lesser emphasis on paediatric populations. This study aims to investigate the pharmacokinetic properties of IgG in paediatric patients with PID and SAD.
Methods
Population pharmacokinetic analysis for PID and SAD children treated with intravenous immunoglobulin at a tertiary paediatric centre was conducted using NONMEM® (7.5.1). Dosing simulations to achieve therapeutic levels of 6 and 8 gL −1 were performed.
Results
A population pharmacokinetic analysis of 64 patients (median age 4.08 years, range 0.06–16.8) was performed. A two‐compartment model with first‐order elimination, incorporating both additive and proportional residual error, adequately described the data. Interindividual variability was modelled on clearance, volume of distribution and baseline IgG levels, with allometric scaling to a 70‐kg body weight applied a priori. The estimated clearance was 0.308 L −1 day −1 70 kg −1 (95% CI 0.23, 0.67), and the volume of distribution was 10.96 L −1 70 kg −1 (95% CI 5.97, 15.79). Patients with SAD exhibited a lower clearance rate of 54% compared with PID patients. Dosing simulations indicated that the recommended SAD dosing regimen maintained therapeutic IgG levels in the simulated population. However, only 44.8% to 51.9% of patients with PID achieved target IgG levels with the standard regimen.
Conclusions
This study provides insights into immunoglobulin pharmacokinetics in paediatric PID and SAD patients, guiding optimised dosing strategies. Administering a loading dose would improve the probability of maintaining therapeutic IgG levels during the 4‐week dosing interval.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection, Immunity and Inflammation Research & Teaching Department, UCL GOS Institute of Child Health, University of London, London, UK.
- Pharmacy Department, Great Ormond Street Hospital, London, Greater London, UK.
- Immunology Department, Great Ormond Street Hospital, London, Greater London, UK.
ORCID-Profile: Iek Leng Cheng, Joseph F Standing
Förderung
- Health Education England (HEE)/NIHR
Zitieren
APA
Cheng, I. L., Huang, Z. H., Worth, A., Booth, C., & Standing, J. F. (2026). Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70420
Vancouver
Cheng IL, Huang ZH, Worth A, Booth C, Standing JF. Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70420
BibTeX
@article{Cheng2026,
author = {Cheng, Iek Leng and Huang, Zhong Hui and Worth, Austen and Booth, Claire and Standing, Joseph F},
title = {Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70420}
}
EUVIMED